UNITED STATES ~~SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549~~

~~FORM~~SECURITIES ~~8-KCURRENT~~AND ~~REPORT~~EXCHANGE COMMISSION

~~PURSUANT~~WASHINGTON, TOD.C. ~~SECTION~~20549 ~~13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~

~~Date~~FORM ~~of Report (Date of earliest event reported): February 10, 2014~~ 8-K

~~CATALENT~~CURRENT ~~PHARMA~~REPORT ~~SOLUTIONS, INC. (Exact name of registrant as specified in its charter)~~

Delaware(State or other jurisdiction of Incorporation)	333-147871 (Commission File Number)		13-3523163 (IRS Employer Identification Number)
14 Schoolhouse RoadSomerset, New Jersey		08873
(Address of registrant’s principal executive office)		(Zip code)

PURSUANT TO SECTION 13 OR 15(d)

~~(732) 537-6200~~OF ~~(Registrant’s~~THE ~~telephone~~SECURITIES ~~number,~~EXCHANGE ~~including~~ACT ~~area~~OF ~~code)~~1934

Date of Report (Date of earliest event reported): July 29, 2014

CATALENT PHARMA SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)


Delaware	333-147871	13-3523163
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

14 Schoolhouse Road Somerset, New Jersey		08873
(Address of registrant’s principal executive office)		(Zip code)

(732) 537-6200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~ITEM 28.~~02 Results~~01 ofOther ~~Operations and Financial Condition~~Events.

On ~~February~~July 1029, 2014, Catalent Pharma Solutions, Inc. (~~the~~ “~~Company~~Catalent”) ~~issued~~provided annotice ~~earnings~~of ~~release~~its ~~setting~~election ~~forth~~to redeem all of the ~~Company~~$350.0 million aggregate principal amount currently outstanding of Catalent’s ~~second~~7.875% ~~quarter~~Senior ~~ended~~Notes ~~December 31,~~due ~~2013~~2018 ~~financial~~(the ~~results~~“Redeemed Notes”). The ~~earnings~~Redeemed ~~release~~Notes iswill ~~furnished~~be asredeemed ~~Exhibit~~on 99August 28, 2014 (the “Redemption Date”) at a redemption price (the “Redemption Price”) of 101.15% ~~hereto~~of the principal amount thereof plus accrued and isunpaid ~~incorporated~~interest ~~herein~~on the Redeemed Notes to, but excluding, the Redemption Date, subject to the completion of an initial public offering by Catalent’s ~~reference~~indirect parent, Catalent, Inc.

AsSIGNATURE provided in General Instruction B.2 of Form 8-K, the information and exhibit contained in this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act’), nor shall they be deemed to be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

~~Item~~Pursuant ~~9.01 Financial~~to ~~Statements~~the ~~and~~requirements ~~Exhibits~~of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

(d) Exhibits. The following Exhibit is furnished as part of this Current Report on Form 8-K.

~~Exhibit~~3 ~~No. Description~~

99.1 Earnings release, February 10, 2014, issued by Catalent Pharma Solutions, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Catalent Pharma Solutions, Inc.

(Registrant)

By: _/s/ Samrat S. Khichi ______

Name: Samrat S. Khichi

Title: Senior Vice President, Chief Administrative Officer, General Counsel and Secretary

Date: February 10, 2014

EXHIBIT LIST

Exhibit No. Description

99.1 Earnings release, February 10, 2014, issued by Catalent Pharma Solutions, Inc.

Catalent Pharma Solutions, Inc.

(Registrant)

Dated: July 29, 2014

/s/ Matthew M. Walsh

Matthew M. Walsh

Executive Vice President & Chief Financial Officer

Filing Compare · Catalent Pharma Solutions, Inc.